Abeona Therapeutics (ABEO) lifts ZEVASKYN revenue 31% in Q2 2026 as cash hits $146.8M
Rhea-AI Filing Summary
Abeona Therapeutics Inc. reported second quarter 2026 results centered on the commercial launch of ZEVASKYN, its autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). Net ZEVASKYN revenue for the quarter ended June 30, 2026 was $11.4 million, a 31% quarter-over-quarter increase from $8.7 million in the first quarter of 2026. Five patients were treated in the quarter, with revenue recognized for four treatments; since launch, 12 treatments have been completed.
The qualified treatment center (QTC) network expanded to seven sites, including recent activations at NewYork-Presbyterian/Columbia, Children’s Hospital of Philadelphia, University of Texas Medical Branch, and Cincinnati Children’s. Abeona highlighted that the Centers for Medicare & Medicaid Services granted ZEVASKYN New Technology Add-On Payment (NTAP) status effective October 1, 2026, intended to support hospital adoption for Medicare patients, who account for about 10% of RDEB patients.
R&D expenses were $5.0 million and SG&A expenses were $15.8 million in Q2 2026, both down versus Q1 2026. The company reported a net loss of $(20.2) million, or $(0.35) per share, and held $146.8 million in cash, cash equivalents and short-term investments as of June 30, 2026, compared with $191.4 million as of December 31, 2025.
Positive
- Net ZEVASKYN revenue grew 31% QoQ to $11.4 million in Q2 2026, up from $8.7 million in Q1 2026, indicating early commercial traction for the newly launched gene therapy.
- Operating expenses declined sequentially, with R&D at $5.0 million and SG&A at $15.8 million in Q2 2026, both lower than in Q1 2026, reflecting reduced one-time and launch-related costs.
- CMS granted NTAP status for ZEVASKYN effective October 1, 2026, creating a supplemental reimbursement pathway that may support hospital adoption and access for Medicare patients.
- QTC network expanded to seven sites, including leading academic centers, broadening the geographic footprint for ZEVASKYN and supporting patient identification and treatment capacity.
Negative
- Net loss was $(20.2) million in Q2 2026, or $(0.35) per share, and included a $(7.2) million loss from change in fair value of warrant liabilities, highlighting continued bottom-line pressure.
- Cash, cash equivalents and short-term investments fell to $146.8 million as of June 30, 2026 from $191.4 million at December 31, 2025, indicating meaningful cash usage over six months.
Filing Explained
3 Q3 treatments were completed by August 13, but 2 launch treatments lacked recognized revenue because of manufacturing or release issues.
This Form 8-K reports Abeona’s second-quarter results and business update. As of the filing, 3 ZEVASKYN treatments had been completed in Q3 to date. Two patients’ treatments did not produce recognized revenue because of low manufacturing yield or failure to meet lot-release specifications, so completed treatments and revenue-recognized treatments are different measures in this update.
Effective
The NTAP disclosure is a payment pathway for eligible hospitals, not revenue Abeona reports as received in this filing. At
Pre-funded warrants convert to shares when exercised; their separate presentation means the filing shows potential share instruments alongside the outstanding common shares, rather than treating all equivalents as outstanding common stock.
8-K Event Classification
Key Figures
Key Terms
New Technology Add-On Payment regulatory
autologous cell-based gene therapy medical
recessive dystrophic epidermolysis bullosa medical
qualified treatment center medical
change in fair value of warrant liabilities financial
Earnings Snapshot
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How did Abeona Therapeutics (ABEO) perform financially in Q2 2026?
What was the growth in ZEVASKYN revenue for Abeona Therapeutics (ABEO)?
What is Abeona Therapeutics’ (ABEO) cash position as of June 30, 2026?
How many patients have been treated with ZEVASKYN at Abeona Therapeutics (ABEO)?
What reimbursement support did Abeona Therapeutics (ABEO) secure for ZEVASKYN?
How has Abeona Therapeutics (ABEO) expanded its ZEVASKYN treatment network?
How did operating expenses trend for Abeona Therapeutics (ABEO) in Q2 2026?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission | (I.R.S. Employer | ||
| of incorporation) | File Number) | Identification No.) |
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
N /A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Title of Each Class | Trading Symbol | Name of each exchange on which registered | ||
| The
|
Securities registered pursuant to Section 12(b) of the Act:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On August 13, 2026, Abeona Therapeutics Inc. issued a press release regarding its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated into this Item 2.02 by reference.
The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press release dated August 13, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Abeona Therapeutics Inc. | ||
| (Registrant) | ||
| By: | /s/ Joseph Vazzano | |
| Name: | Joseph Vazzano | |
| Title: | Chief Financial Officer | |
| Date: August 13, 2026 | ||
Exhibit 99.1
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
- Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million –
- Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since launch, 12 treatments completed –
- Expanding QTC network now includes seven sites nationwide; growing number of QTCs progressing patients through treatment process –
- $146.8 million in cash, cash equivalents and short-term investments as of June 30, 2026 –
CLEVELAND, August 13, 2026 – Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the second quarter of 2026 and provided an update on commercial execution for ZEVASKYN (prademagene zamikeracel).
Commercial Update
Steady launch-year growth for ZEVASKYN. Commercial execution continued to strengthen during the second quarter of 2026 with five patients treated with ZEVASKYN. In the third quarter of 2026 to-date, three patients have completed treatments. Since launch, 12 patient treatments have been completed. Revenue was not recognized for two patients due to low manufacturing yield or not meeting lot release specifications.
Expanded qualified treatment center (QTC) network and increased patient onboarding. Abeona continues to expand the ZEVASKYN QTC network, and the number of QTCs that have treated patients with ZEVASKYN has increased. Key recent milestones include:
| - | NewYork-Presbyterian/Columbia University Irving Medical Center and Children’s Hospital of Philadelphia (CHOP) were activated as QTCs during the second quarter of 2026. | |
| - | CHOP and University of Texas Medical Branch (UTMB) have commenced collection of patient biopsies, and CHOP has treated its first patient with ZEVASKYN. | |
| - | In the third quarter of 2026, Abeona announced the activation of Cincinnati Children’s as the newest ZEVASKYN QTC. Cincinnati Children’s is one of the largest epidermolysis bullosa treatment centers in the U.S. |
Secured CMS New Technology Add-On Payment (NTAP) status for ZEVASKYN. Effective October 1, 2026, ZEVASKYN will have NTAP status under the fiscal year 2027 Hospital Inpatient Prospective Payment System Final Rule from the Centers for Medicare & Medicaid Services (CMS). NTAP provides a pathway for eligible hospitals to receive a supplemental payment from CMS, in addition to the base diagnosis-related group (DRG) payment, when treating Medicare beneficiaries with ZEVASKYN. This designation is expected to support hospital adoption and help facilitate access for Medicare patients, who represent approximately 10 percent of RDEB patients.
Continued engagement raising RDEB community awareness. The Company presented 5-year long-term follow-up data after ZEVASKYN application from the VIITAL Phase 3 clinical study and a case report from the longest follow-up of 12 years from the Phase 1/2a study. Presentations were made at key medical congresses, including the Society for Investigative Dermatology (SID) and Society for Pediatric Dermatology (SPD) annual meetings, as well as the debra Care Conference, to drive physician awareness, patient identification, and enable patient referral to the expanding QTC network.
“Our confidence in ZEVASKYN’s substantial opportunity is reinforced by our launch progress and experience to date as we engage with a growing number of patients and expand our QTC network,” said Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics. “As early real-world experience with ZEVASKYN matures across activated sites, we expect to drive broader adoption and long-term growth.”
Second Quarter 2026 Financial Results
Net ZEVASKYN revenue for the quarter ended June 30, 2026 increased 31% quarter-over-quarter to $11.4 million, compared to $8.7 million in the first quarter of 2026. While five patients were treated with ZEVASKYN during the second quarter of 2026, revenue was recognized for four treatments as one batch yielded fewer than the threshold number of sheets for revenue recognition.
Research and development (R&D) expenses were $5.0 million for the second quarter of 2026 compared to $9.6 million in the first quarter of 2026, which included the one-time, up-front cost of $7.0 million for in-licensing ABO-701.
Selling, general and administrative expenses were $15.8 million for the second quarter of 2026, compared to $19.5 million for the first quarter of 2026. The decrease primarily reflects fewer engineering runs and less manufacturing training costs in the second quarter of 2026.
Net loss was $(20.2) million, or $(0.35) per basic and diluted common share, for the quarter ended June 30, 2026. Net loss for the first quarter of 2026 was $(17.1) million, or $(0.30) per basic and diluted common share.
Cash, cash equivalents and short-term investments totaled $146.8 million as of June 30, 2026, compared to $191.4 million as of December 31, 2025.
Conference Call Details
The Company will host a conference call and webcast on August 13, 2026, at 8:30 a.m. ET to discuss its financial results and corporate progress. To access the call, dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and Entry Code: 245916 five minutes prior to the start of the call. A live, listen-only webcast can be accessed on the Investors & Media section of Abeona’s website at https://investors.abeonatherapeutics.com/events. An archived webcast replay will be available for 30 days following the call.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio, serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features ABO-701 (PSMA-SIR-T™), a potentially first-in-class engineered T-cell therapy targeting PSMA, engineered to overcome the core failures of cell therapies in solid tumors. For more information, visit www.abeonatherapeutics.com.
ZEVASKYN®, Abeona Assist®, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to our ability to maintain existing and obtain additional regulatory approvals of ZEVASKYN® and any future product candidates; our ability to successfully commercialize and market ZEVASKYN® and any future product candidates, if approved, and the timing of any commercialization and marketing efforts; our ability to manufacture sufficient batches of ZEVASKYN® to meet demand; our ability to manufacture ZEVASKYN® batches that meet certain product release specifications that were required by FDA at the time of BLA approval and implemented based on a limited clinical dataset; the FDA’s willingness to revise such release specifications to reflect real-world manufacturing experience; our ability to manufacture from provided biopsy material a ZEVASKYN® batch for which revenue may ultimately be recognized, which depends on such factors as qualified treatment centers obtaining biopsy samples from ZEVASKYN® patients of sufficient quality to act as starting material for manufacturing ZEVASKYN®, patient-to-patient variability in cell growth during the ZEVASKYN® manufacturing process, patient health deterioration in close proximity to ZEVASKYN® treatment such that treatment is no longer possible, and expiration of ZEVASKYN®’s 84-hour shelf-life before surgical application of ZEVASKYN® can be performed; our ability to activate additional qualified treatment centers to administer ZEVASKYN® on patients; the ability of qualified treatment centers to enroll patients for treatment or administer ZEVASKYN® on patients; our ability submit an investigational new drug application for ABO-701 and enroll patients in new clinical trials; our ability to access additional financial resources and/or our financial flexibility to reduce operating expenses if required; our ability to obtain additional equity funding from current or new stockholders; the potential impact of unpredicted changes in the structure and/or administration of the United States government or its agencies; our ability to out-license technology and/or other assets, deferring and/or eliminating planned expenditures, restructuring operations and/or reducing headcount, and sales of assets; the dilutive effect that raising additional funds by selling additional equity securities would have on the relative equity ownership of our existing investors, including under our existing at-the-market sale agreement; the outcome of any interactions with the FDA or other regulatory agencies relating to any of our products or product candidates; our ability to continue to secure and maintain regulatory designations for our product candidates; our ability to develop manufacturing capabilities compliant with current good manufacturing practices for our product candidates; our ability to manufacture cell and gene therapy products and produce an adequate product supply to support clinical trials and potentially future commercialization; the rate and degree of market acceptance of our product candidates for any indication once approved; our ability to meet our obligations contained in license agreements to which we are party; and macroeconomic uncertainty resulting from changes to U.S. trade policy, including current or future tariffs or other trade restrictions.
Contacts:
Investor and Media
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
ir@abeonatherapeutics.com
Investor
Lee M. Stern
Meru Advisors
lstern@meruadvisors.com
ABEONA THERAPEUTICS INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(In thousands, except share and per share amounts)
(Unaudited)
| For the three months ended June 30, | For the six months ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenues: | ||||||||||||||||
| Product revenue, net | $ | 11,380 | $ | — | $ | 20,100 | $ | — | ||||||||
| License and other revenues | — | 400 | — | 400 | ||||||||||||
| Total revenues | 11,380 | 400 | 20,100 | 400 | ||||||||||||
| Costs and expenses: | ||||||||||||||||
| Cost of sales | 4,177 | — | 6,873 | — | ||||||||||||
| Royalties | — | 100 | — | 100 | ||||||||||||
| Research and development | 5,021 | 5,943 | 14,576 | 15,884 | ||||||||||||
| Selling, general and administrative | 15,835 | 17,149 | 35,337 | 26,935 | ||||||||||||
| Total costs and expenses | 25,033 | 23,192 | 56,786 | 42,919 | ||||||||||||
| Loss from operations | (13,653 | ) | (22,792 | ) | (36,686 | ) | (42,519 | ) | ||||||||
| Interest income | 1,355 | 1,027 | 2,709 | 2,337 | ||||||||||||
| Interest expense | (696 | ) | (957 | ) | (1,526 | ) | (1,955 | ) | ||||||||
| Change in fair value of warrant liabilities | (7,191 | ) | (5,388 | ) | (1,805 | ) | 1,857 | |||||||||
| Gain from sale of priority review voucher, net | — | 152,366 | — | 152,366 | ||||||||||||
| Other (loss) income, net | (6 | ) | 89 | 44 | 230 | |||||||||||
| Income (loss) before income taxes | (20,191 | ) | 124,345 | (37,264 | ) | 112,316 | ||||||||||
| Income tax expense | — | 15,512 | 2 | 15,512 | ||||||||||||
| Net (loss) income | $ | (20,191 | ) | $ | 108,833 | $ | (37,266 | ) | $ | 96,804 | ||||||
| Basic (loss) income per common share | $ | (0.35 | ) | $ | 2.07 | $ | (0.66 | ) | $ | 1.89 | ||||||
| Dilutive (loss) income per common share | $ | (0.35 | ) | $ | 1.71 | $ | (0.66 | ) | $ | 1.47 | ||||||
| Weighted average number of common shares outstanding: | ||||||||||||||||
| Basic | 57,048,385 | 52,524,510 | 56,835,833 | 51,159,240 | ||||||||||||
| Dilutive | 57,048,385 | 66,640,620 | 56,835,833 | 65,111,330 | ||||||||||||
ABEONA THERAPEUTICS INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(In thousands, except share amounts)
(Unaudited)
| June 30, 2026 | December 31, 2025 | |||||||
| Cash, cash equivalents and short-term investments | $ | 146,826 | $ | 191,404 | ||||
| Total assets | $ | 179,507 | $ | 219,570 | ||||
| Total liabilities | $ | 51,449 | $ | 60,354 | ||||
| Total stockholders’ equity | $ | 128,058 | $ | 159,216 | ||||
| Common stock outstanding | 57,225,919 | 55,043,413 | ||||||
| Common stock and common stock equivalents* | 71,098,537 | 69,103,212 | ||||||
| *Common stock and common stock equivalents: | ||||||||
| Common stock | 57,225,919 | 55,043,413 | ||||||
| Common stock warrants (pre-funded) | 4,933,489 | 5,113,321 | ||||||
| Common stock and pre-funded warrants | 62,159,408 | 60,156,734 | ||||||
| Options to purchase common stock | 168,670 | 176,019 | ||||||
| Conversion option to redeem common stock | 614,251 | 614,251 | ||||||
| Warrants to purchase common stock | 8,156,208 | 8,156,208 | ||||||
| Total common stock and common stock equivalents | 71,098,537 | 69,103,212 | ||||||